Evidence map›Paper›PMID 35530361›Full record

ArticleFrontiers in oncology2022

Adiponectin Deficiency Enhances Anti-Tumor Immunity of CD8

Jiao Peng, Haifeng Huang, Qiuchan Huan, Chenghui Liao, Zebin Guo, Die Hu, Xiangchun Shen, Haitao Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jiao PengDepartment of Pharmacy, Peking University Shenzhen Hospital, Shenzhen, China.
Haifeng HuangSchool of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
Qiuchan HuanThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China.
Chenghui LiaoSchool of Pharmaceutical Science, Harbin Medical University, Heilongjiang, China.
Zebin GuoSchool of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
Die HuDepartment of Pharmacy, Peking University Shenzhen Hospital, Shenzhen, China.
Xiangchun ShenThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China.
Haitao XiaoSchool of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
Guiyang Medical University · CNShenzhen University Health Science Center · CNHarbin Medical University · CNPeking University Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Restoring the tumor-killing function of CD8

Indexed as

adiponectinanti-tumor immunityCD8+ T cellsrhabdomyosarcomaSTAT3

Identifiers

PMID35530361
PMCPMC9074303
OpenAlexW4224246163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.